NASDAQ: ZNTLZentalis Pharmaceuticals Inc Stock
$4.92+0.25 (+5.35%)
Updated Jul 30, 2026
ZNTL Price
$4.92
Fair Value Price
-$0.05
Market Cap
$350.24M
52 Week Low
$1.21
52 Week High
$6.95
P/E
-2.84x
P/B
1.92x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$124.13M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.39
Operating Cash Flow
-$126M
Beta
1.75
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ZNTL Overview
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ZNTL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ZNTL
Ranked#372 of 462
Ranked#372 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $258.38 | A | |
| $11.06 | A | |
| $8.42 | A |
Be the first to know about important ZNTL news, forecast changes, insider trades & much more!
ZNTL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZNTL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZNTL ($4.92) is overvalued by 9,971.45% relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ZNTL ($4.92) is not significantly undervalued (9,971.45%) relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ZNTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ZNTL due diligence checks available for Premium users.
Valuation
ZNTL fair value
Fair Value of ZNTL stock based on Discounted Cash Flow (DCF)
Price
$4.92
Fair Value
-$0.05
Undervalued by
9,971.45%
ZNTL ($4.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ZNTL ($4.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ZNTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ZNTL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.84x
Industry
20.57x
Market
17.04x
ZNTL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.92x
Industry
5.4x
ZNTL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZNTL's financial health
Profit margin
Revenue
$0.0
Net Income
-$35.4M
Profit Margin
0%
ZNTL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$253.1M
Liabilities
$70.4M
Debt to equity
0.39
ZNTL's short-term assets ($218.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZNTL's short-term assets ($218.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZNTL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ZNTL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$33.0M
Investing
$30.0M
Financing
-$1.1M
ZNTL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ZNTL vs Biotech Stocks
Zentalis Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.